194 related articles for article (PubMed ID: 29173976)
1. Phase 2 Study of Weekly Paclitaxel Plus Estramustine in Metastatic Hormone-Refractory Prostate Carcinoma: ECOG-ACRIN Cancer Research Group (E1898) Trial.
Wong YN; Manola J; Hudes GR; Roth BJ; Moul JW; Barsevick AM; Scher RM; Volk MJ; Vaughn DJ; Williams SD; Fisch MJ; Cella D; Carducci MA; Wilding G
Clin Genitourin Cancer; 2018 Apr; 16(2):e315-e322. PubMed ID: 29173976
[TBL] [Abstract][Full Text] [Related]
2. An active regimen of weekly paclitaxel and estramustine in metastatic androgen-independent prostate cancer.
Vaishampayan U; Fontana J; Du W; Hussain M
Urology; 2002 Dec; 60(6):1050-4. PubMed ID: 12475668
[TBL] [Abstract][Full Text] [Related]
3. Weekly paclitaxel plus estramustine combination therapy in hormone-refractory prostate cancer: a pilot study.
Kuruma H; Fujita T; Shitara T; Egawa S; Yokoyama E; Baba S
Int J Urol; 2003 Sep; 10(9):470-5. PubMed ID: 12941125
[TBL] [Abstract][Full Text] [Related]
4. A Phase I/II study of weekly paclitaxel and 3 days of high dose oral estramustine in patients with hormone-refractory prostate carcinoma.
Ferrari AC; Chachoua A; Singh H; Rosenthal M; Taneja S; Bednar M; Mandeli J; Muggia F
Cancer; 2001 Jun; 91(11):2039-45. PubMed ID: 11391583
[TBL] [Abstract][Full Text] [Related]
5. Phase 2 Study of Cyclophosphamide, Etoposide, and Estramustine in Patients With Castration-Resistant Prostate Cancer.
Laber DA; Chen MB; Jaglal M; Patel A; Visweshwar N
Clin Genitourin Cancer; 2018 Dec; 16(6):473-481. PubMed ID: 30072309
[TBL] [Abstract][Full Text] [Related]
6. Phase II randomized trial of weekly paclitaxel with or without estramustine phosphate in progressive, metastatic, hormone-refractory prostate cancer.
Berry WR; Hathorn JW; Dakhil SR; Loesch DM; Jackson DV; Gregurich MA; Newcomb-Fernandez JK; Asmar L
Clin Prostate Cancer; 2004 Sep; 3(2):104-11. PubMed ID: 15479494
[TBL] [Abstract][Full Text] [Related]
7. Combination chemotherapy with paclitaxel, estramustine and carboplatin for hormone refractory prostate cancer.
Urakami S; Igawa M; Kikuno N; Yoshino T; Kishi H; Shigeno K; Shiina H
J Urol; 2002 Dec; 168(6):2444-50. PubMed ID: 12441936
[TBL] [Abstract][Full Text] [Related]
8. Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data.
Fizazi K; Le Maitre A; Hudes G; Berry WR; Kelly WK; Eymard JC; Logothetis CJ; Pignon JP; Michiels S;
Lancet Oncol; 2007 Nov; 8(11):994-1000. PubMed ID: 17942366
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer.
Hudes GR; Nathan F; Khater C; Haas N; Cornfield M; Giantonio B; Greenberg R; Gomella L; Litwin S; Ross E; Roethke S; McAleer C
J Clin Oncol; 1997 Sep; 15(9):3156-63. PubMed ID: 9294479
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy with or without estramustine for treatment of castration-resistant prostate cancer: A systematic review and meta-analysis.
Qin Z; Li X; Zhang J; Tang J; Han P; Xu Z; Yu Y; Yang C; Wang C; Xu T; Xu Z; Zou Q
Medicine (Baltimore); 2016 Sep; 95(39):e4801. PubMed ID: 27684806
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma.
Smith DC; Chay CH; Dunn RL; Fardig J; Esper P; Olson K; Pienta KJ
Cancer; 2003 Jul; 98(2):269-76. PubMed ID: 12872344
[TBL] [Abstract][Full Text] [Related]
12. Multicenter Phase II study of estramustine phosphate plus weekly paclitaxel in patients with androgen-independent prostate carcinoma.
Vaughn DJ; Brown AW; Harker WG; Huh S; Miller L; Rinaldi D; Kabbinavar F
Cancer; 2004 Feb; 100(4):746-50. PubMed ID: 14770430
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of weekly paclitaxel plus oral estramustine phosphate in patients with hormone-refractory prostate cancer.
Haas N; Roth B; Garay C; Yeslow G; Entmacher M; Weinstein A; Rogatko A; Babb J; Minnitti C; Flinker D; Gillon T; Hudes G
Urology; 2001 Jul; 58(1):59-64. PubMed ID: 11445480
[TBL] [Abstract][Full Text] [Related]
14. Effective and Safe Administration of Low-Dose Estramustine Phosphate for Castration-Resistant Prostate Cancer.
Inoue T; Ogura K; Kawakita M; Tsukino H; Akamatsu S; Yamasaki T; Matsui Y; Segawa T; Sugino Y; Kamoto T; Kamba T; Tanaka S; Ogawa O
Clin Genitourin Cancer; 2016 Feb; 14(1):e9-e17. PubMed ID: 26433627
[TBL] [Abstract][Full Text] [Related]
15. Hormone refractory advanced prostate cancer treated with estramustine and paclitaxel combination.
Athanasiadis A; Tsavdaridis D; Rigatos SK; Athanasiadis I; Pergantas N; Stathopoulos GP
Anticancer Res; 2003; 23(3C):3085-8. PubMed ID: 12926166
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer.
Smith DC; Esper P; Strawderman M; Redman B; Pienta KJ
J Clin Oncol; 1999 Jun; 17(6):1664-71. PubMed ID: 10561202
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of oral estramustine and 3-hr infusional paclitaxel for the treatment of hormone refractory prostate cancer.
Kuzel TM; Kies MS; Wu N; Hsieh YC; Rademaker AW
Cancer Invest; 2002; 20(5-6):634-43. PubMed ID: 12197218
[TBL] [Abstract][Full Text] [Related]
18. Weekly paclitaxel, estramustine phosphate, and oral etoposide in the treatment of hormone-refractory prostate carcinoma: results of a Minnie Pearl Cancer Research Network phase II trial.
Meluch AA; Greco FA; Morrissey LH; Raefsky EL; Steis RG; Butts JA; Hainsworth JD;
Cancer; 2003 Nov; 98(10):2192-8. PubMed ID: 14601089
[TBL] [Abstract][Full Text] [Related]
19. Monthly paclitaxel and carboplatin with oral estramustine phosphate in patients with hormone-refractory prostate cancer.
Segawa T; Kamoto T; Kinoshita H; Kunishima Y; Yoshimura K; Ito A; Takahashi T; Higashi S; Nakamura E; Nishiyama H; Ito N; Yamamoto S; Habuchi T; Ogawa O
Int J Clin Oncol; 2005 Oct; 10(5):333-7. PubMed ID: 16247660
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of paclitaxel and estramustine in patients with recurrent and refractory non-Hodgkin lymphoma.
Borghaei H; Millenson M; Schilder R; Alden M; Rogatko A; Wang H; Padavic-Shaller K; Smith MR
Cancer; 2004 Nov; 101(9):2034-41. PubMed ID: 15455357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
